American Society of Echocardiography

HeartSciences Announces Podium Presentation at World Congress of Anesthesiologists on the Utility of MyoVista® Wavelet ECG For Detection of Left Ventricular Diastolic Dysfunction in Preoperative Patients

Retrieved on: 
Tuesday, March 26, 2024
Diabetes, Disease, Echocardiography, HSCS, Congress, Algorithm, Intelligence, Anesthesia, Patient, Mortality, LVDD, Society, Anesthesiology, Type, Use, American Society of Echocardiography, Medical device

Preoperative left ventricular diastolic dysfunction (LVDD) is very common and one of the important causes of perioperative morbidity and mortality in cardiac and non-cardiac surgeries.

Key Points: 
  • Preoperative left ventricular diastolic dysfunction (LVDD) is very common and one of the important causes of perioperative morbidity and mortality in cardiac and non-cardiac surgeries.
  • In the study, patients undergoing preoperative anesthesia evaluation for cardiac and non-cardiac surgeries were enrolled.
  • For patients indicated for preoperative echocardiography, LVDD was diagnosed and graded as per American Society of Echocardiography (ASE) guidelines and a MyoVista wavECG was also performed.
  • Based on these findings, 25 of the 60 non-LVDD patients could be safely excluded from referral to preoperative echocardiography.

HeartSciences Expands its Scientific Advisory Board

Retrieved on: 
Monday, February 12, 2024
Bangladesh Technical Education Board, Accreditation, HSCS, American Society of Echocardiography, Algorithm, Research, American Heart Association, Artificial intelligence, AI, Intelligence, Assistant, FDA, Outcomes research, Diagnostic medical sonography, ECG, Education, Society, GE HealthCare, American College, Journal, Machine learning, Harvard Medical School, ACC, Commission, Medical device

Southlake, TX, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced the appointment of Jordan B. Strom M.D., M.Sc., to its Scientific Advisory Board.

Key Points: 
  • Southlake, TX, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced the appointment of Jordan B. Strom M.D., M.Sc., to its Scientific Advisory Board.
  • Strom has been assisting us in recent interactions with the FDA and we are delighted to welcome him to our Scientific Advisory Board as we prepare for FDA submission of our MyoVista device and cloud platform, in addition to algorithms licensed from the Icahn School of Medicine at Mount Sinai, New York.
  • Dr. Strom has expertise in AI-based medical devices and is a consultant to GE Healthcare, Phillips Healthcare, and Edwards Life Sciences.
  • HeartSciences is an innovator in this field, and I look forward to helping them unleash the potential power of AI-powered ECGs to help clinicians deliver timely and optimal care.

JenaValve Announces Partnership with the American Society of Echocardiography (ASE) to Advance Detection and Diagnosis of Aortic Regurgitation

Retrieved on: 
Thursday, November 16, 2023
Aortic regurgitation, IRT, Patient, Cardiovascular disease, American Society of Echocardiography, MD, Diagnosis, Partnership, Echocardiography, THV, Physician, Society, ASE, Health, Education, Medical imaging

Together, JenaValve and ASE will work to drive increased awareness and education of cardiac imaging for the detection and diagnosis of aortic regurgitation (AR).

Key Points: 
  • Together, JenaValve and ASE will work to drive increased awareness and education of cardiac imaging for the detection and diagnosis of aortic regurgitation (AR).
  • “Echocardiography is fundamental to the detection and diagnosis of AR.
  • They bring a unique perspective to echocardiography for heart valve disease,” said Benjamin Eidem, MD, FASE, President of ASE.
  • “This partnership helps both ASE and JenaValve accomplish our shared goal of improving patient care for those suffering from AR.”

Us2.ai Partners with Leading Academic Medical Center to Collaborate on AI-Enabled Echocardiography Software

Retrieved on: 
Wednesday, September 13, 2023
Technology, Clinical Trials, Health Technology, Cardiology, Software, Biotechnology, Health, General Health, Artificial Intelligence, PW, Heart, Duke University, CE, Partnership, Society, CW, American Society of Echocardiography, Health policy, Graduate Medical School Admissions Test, Heart failure, Anesthesiology, Echocardiography, Deep learning, Nasiriyah Heart Center, Splenic infarction, Associate, 2D, Duke University School of Medicine, Ischemia, Patient, Valvular heart disease, Algorithm, Artificial intelligence, Diagnosis, Cardiomyopathy, Duke University Health System, FDA, Pulmonary hypertension, Duke–NUS Medical School, Syndrome, Medtech, Medical device, Medical imaging, Doppler effect, Medicine

In clinical practice, echocardiography is now firmly established as a central, affordable front-line tool for diagnosis and management of a range of cardiac conditions.

Key Points: 
  • In clinical practice, echocardiography is now firmly established as a central, affordable front-line tool for diagnosis and management of a range of cardiac conditions.
  • Even at the most well-resourced setting, the process of acquiring, measuring, and analyzing the images is time-consuming and labor-intensive, making the routine echocardiography application unsustainable.
  • Advances in deep learning have made automated analysis of medical images possible,” said Dr. Manesh Patel, Chief of Cardiology and Co-Director of the Heart Center at Duke University Health System.
  • This covers the vast majority of standard measurements for adult transthoracic echocardiography recommended by the American Society of Echocardiography, European Association of Cardiovascular Imaging, and British Society of Echocardiography.

Study Confirms Ultromics' AI Can Improve HFpEF Detection Using a Single Echocardiogram View

Retrieved on: 
Monday, July 31, 2023
Mayo Clinic, Saint George, Education, Hospital, Survival, Eye, University Hospitals Cleveland Medical Center, Research, Heart failure with preserved ejection fraction, Doctor of Philosophy, Incidence, M.D, TTE, Patient, Data, Institutional review board, NHS foundation trust, ASE, Artificial intelligence, Heart failure, Diagnosis, Mortality, AI, FDA, Health, Society, American Society of Echocardiography, Disease, Medical device, Medical imaging, Pharmaceutical industry, Nursing

OXFORD, England, July 31, 2023 /PRNewswire/ -- Applying AI to a single apical four chamber (A4C) view echocardiogram provides accurate information to detect heart failure with preserved ejection fraction (HFpEF), according to research published today in JACC Advances.1

Key Points: 
  • Ultromics' EchoGo® Heart Failure accurately detected HFpEF and provided fewer non-diagnostic outputs than current clinical scores, using just the routinely acquired A4C view from a transthoracic echocardiographic (TTE).
  • As the first AI platform cleared to detect the condition, EchoGo® Heart Failure can fill a significant unmet need."
  • Ross Upton, PhD, CEO and Founder of Ultromics, said: "Our research demonstrates the tremendous potential of AI in revolutionizing the detection of HFpEF.
  • Automated Echocardiographic Detection of Heart Failure with Preserved Ejection Fraction using Artificial Intelligence.

CMS Establishes HCPCS code for Ultromics EchoGo® Heart Failure, Accelerating Access to Precision HFpEF Detection

Retrieved on: 
Wednesday, July 5, 2023
US Foods, CMS, OPPS, Heart failure, Prevalence, Centers for Medicare & Medicaid Services, Food and Drug Administration, Heart failure with preserved ejection fraction, Medicare, Hospital, Patient, ASE, Diagnosis, HCPCS, FDA, Society, Food, American Society of Echocardiography, Medical device, Medical imaging

The new HCPCS code went into effect on July 1st, 2023.

Key Points: 
  • The new HCPCS code went into effect on July 1st, 2023.
  • EchoGo® Heart Failure is the first US Food and Drug Administration (FDA) cleared platform for detecting Heart Failure with Preserved Ejection Fraction (HFpEF), using a single view of an echocardiogram.
  • CMS's position is supported by clinical evidence presented at the American Society of Echocardiography (ASE) 2023 Scientific Sessions , demonstrating the effectiveness of EchoGo® Heart Failure for the detection of HFpEF.
  • The assigned HCPCS code (C9786) brings Ultromics one step closer to transforming cardiovascular care and solidifying its position as a leader in the field.

UltraSight and EchoNous Partner to Enable More Accessible Cardiac Ultrasound for Patients

Retrieved on: 
Friday, June 23, 2023
American Society of Echocardiography, Heart, Plague, Partnership, Stanford University, Cardiovascular technologist, Intelligence, Android, Doctor of Philosophy, IOS, Acquisition, Patient, ASE, Diagnosis, FDA, Society, Medical device, Medical imaging, MD, Cosmos

NATIONAL HARBOR, Md., June 23, 2023 /PRNewswire/ -- Today, UltraSight, a digital health pioneer transforming cardiac imaging through the power of artificial intelligence, announced a partnership with point-of-care ultrasound innovator EchoNous, to enable more healthcare professionals to perform cardiac ultrasound and help increase patient access to cardiac care. The new collaboration was announced at ASE 2023, the premier event for bringing together echo professionals.

Key Points: 
  • NATIONAL HARBOR, Md., June 23, 2023 /PRNewswire/ -- Today, UltraSight , a digital health pioneer transforming cardiac imaging through the power of artificial intelligence, announced a partnership with point-of-care ultrasound innovator EchoNous, to enable more healthcare professionals to perform cardiac ultrasound and help increase patient access to cardiac care.
  • "Empowering a greater number of healthcare professionals in more care settings to conduct cardiac ultrasound brings us one step closer to realizing our vision of making cardiac care more equitable for patients around the world," said UltraSight CEO Davidi Vortman.
  • UltraSight's real-time AI guidance software will be integrated with EchoNous' KOSMOS handheld ultrasound device with the goal of enabling chronic cardiac patient monitoring to be done closer to patients.
  • By separating the acquisition and interpretation of ultrasound images, UltraSight technology has the potential to improve access to optimized cardiac care and more cost-effective heart monitoring opportunities.

Visura Technologies Presents TEECAD Real-World Clinical Data at ASE 2023

Retrieved on: 
Tuesday, June 20, 2023
American Society of Echocardiography, Shaare Zedek Medical Center, Letter, Mayo Clinic, Esophagus, Journal, Physician, TEE, ASE, Intubation, Coffee, Clinical professor, Echocardiography, Cardiology, FDA, Society, Safety, Medical imaging, MD

MINNEAPOLIS, June 20, 2023 /PRNewswire/ -- Visura Technologies, Inc., a privately-held medical device company dedicated to delivering state-of-the-art visualization solutions to improve the safety and success of transesophageal echocardiogram (TEE) probe intubations, announced today it will be attending the American Society of Echocardiography's (ASE) 34th Annual Scientific Sessions in Baltimore, MD June 23-26. At this year's meeting, the TEECAD system will be highlighted in an abstract poster presentation by Sunil Mankad MD, Professor of Medicine, and Director of Transesophageal Echocardiography at the Mayo Clinic in Rochester, MN on Sunday, June 25 at 2:00 pm. In addition, Visura will release a new 15 patient TEECAD white paper from a world-renowned heart center.

Key Points: 
  • In addition, Visura will release a new 15 patient TEECAD white paper from a world-renowned heart center.
  • "The presentation of the clinical data from Mayo Clinic is an important milestone for Visura and real-time visualization for TEE procedures," said David Marmor, Cardiologist at Shaare Zedek Medical Center in Jerusalem, Israel and Founder of Visura Technologies.
  • Clinical data continues to support the need for sighted-TEE intubation to reduce TEE-related complications and increase first pass intubation success.
  • Visit Visura and the TEECAD Innovation Station at ASE booth 513 to learn more.

Maria Ansari, MD, FACC, Named CEO and Executive Director of The Permanente Medical Group, and President and CEO of Mid-Atlantic Permanente Medical Group

Retrieved on: 
Thursday, June 1, 2023
Kaiser Permanente, University, American College of Cardiology, Culture, COVID-19, FACC, San Francisco Department of Public Health, Public health, Trust, UCSF, Physician, Nursing, Patient, Internal medicine, Harvard Business School, FACS, American College, Health, Environment, Society, TPMG, BC Children's Hospital Foundation, American Society of Echocardiography, Management, Hospital, Science, Medicine, MD, Cardiology

OAKLAND, Calif., June 1, 2023 /PRNewswire/ -- The Permanente Medical Group (TPMG) and Mid-Atlantic Permanente Medical Group (MAPMG) today announced that Maria Ansari, MD, FACC, has officially assumed the roles of CEO and executive director of The Permanente Medical Group and president and CEO of the Mid-Atlantic Permanente Medical Group.

Key Points: 
  • OAKLAND, Calif., June 1, 2023 /PRNewswire/ -- The Permanente Medical Group (TPMG) and Mid-Atlantic Permanente Medical Group (MAPMG) today announced that Maria Ansari, MD, FACC, has officially assumed the roles of CEO and executive director of The Permanente Medical Group and president and CEO of the Mid-Atlantic Permanente Medical Group .
  • Dr. Ansari becomes the first woman to lead TPMG, the largest physician-led medical group in the nation, and MAPMG.
  • Dr. Ansari had served as physician-in-chief and chief of staff at Kaiser Permanente San Francisco Medical Center since 2014.
  • "I am tremendously honored to assume the role of CEO of both The Permanente Medical Group and the Mid-Atlantic Permanente Medical Group, and to co-lead The Permanente Federation," Dr. Ansari said.

American Society of Echocardiography Releases New EchoGuide™ App

Retrieved on: 
Wednesday, November 9, 2022
GLOBE, American Society of Echocardiography, Veterinarian, Society, Technology, Diagnosis, Decision-making, Abbott, Disease, Nursing, University, Physician, Social media, Algorithm, Table, ASE, Medical device, Medical imaging, Facebook, MD

EchoGuide is a calculator and algorithm app based on key guidelines published by ASE.

Key Points: 
  • EchoGuide is a calculator and algorithm app based on key guidelines published by ASE.
  • The free app offers physicians and sonographers quick access to common and challenging echocardiography measurements and values.
  • "The ASE EchoGuide app is a fantastic tool for echocardiographers, sonographers, and fellows in training that brings the comprehensive ASE guidelines to their fingertips.
  • The American Society of Echocardiography (ASE) is the Society for Cardiovascular Ultrasound Professionals.